8-K: Genprex Secures Key Patent in Singapore for Reqorsa Combination Therapy

Genprex has been granted a patent in Singapore for its Reqorsa gene therapy in combination with anti-PD-1 antibodies, expanding its global intellectual property portfolio.

Summary

• Genprex has received a patent from the Singapore Patent Office for the use of its lead drug candidate, Reqorsa, in combination with anti-PD-1 antibodies.
• This patent extends protection for this combination therapy through 2037.
• The Singapore patent adds to existing patents in the U.S., Japan, Mexico, Russia, Australia, Chile, China, and Korea.
• The Korean patent also covers the use of Reqorsa with PD-L1 antibodies.
• Genprex is pursuing additional patent applications for Reqorsa and PD-L1 antibody combinations in the U.S., Brazil, Canada, China, Europe, and Israel.
• These patents, if granted, would be relevant to Genprex's Acclaim-3 clinical trial.
• The Acclaim-3 trial is a Phase 1/2 study using Reqorsa and Genentech's Tecentriq as maintenance therapy for extensive stage small cell lung cancer patients.
• The Acclaim-3 trial has received FDA Fast Track and Orphan Drug Designations.

Sentiment

Score: 7

Explanation: The news of the patent grant is positive and strengthens the company's intellectual property position. However, the company still faces risks related to clinical trials and funding.

Positives

• The Singapore patent strengthens Genprex's intellectual property position globally.
• The patent covers a key combination therapy, potentially enhancing the value of Reqorsa.
• The expansion of patent protection to include PD-L1 antibodies is a positive development.
• The patents support the ongoing Acclaim-3 clinical trial, which has received FDA designations.

Risks

• There is no guarantee that the additional patent applications will be granted.
• The success of the Acclaim-3 clinical trial is not assured.
• The commercialization of Reqorsa is subject to regulatory approvals and market acceptance.
• The company's ability to maintain compliance with Nasdaq listing requirements and secure future funding is not guaranteed.

Future Outlook

Genprex plans to pursue additional patent applications for REQORSA and PD-L1 antibody combinations in several countries. The company will continue to advance the clinical development of its product candidates, including the Acclaim-3 trial.

Management Comments

• Genprex noted that the patent expands on previously granted patents to cover the use of REQORSA in combination with an immune checkpoint inhibitor, i.e., PD-1 antibodies.

Industry Context

The announcement is relevant to the immuno-oncology space, where combination therapies involving checkpoint inhibitors and other treatments are becoming increasingly important. Genprex's focus on combining Reqorsa with PD-1 and PD-L1 antibodies aligns with this trend.

Comparison to Industry Standards

• The granting of patents for combination therapies is a common practice in the pharmaceutical industry, particularly in oncology.
• Companies like Merck (Keytruda) and Bristol-Myers Squibb (Opdivo) have also pursued similar strategies with their checkpoint inhibitors.
• Genprex's approach of combining gene therapy with checkpoint inhibitors is a novel approach that could differentiate it from competitors.
• The success of the Acclaim-3 trial will be crucial in determining the competitive positioning of Genprex's therapy.

Stakeholder Impact

• The patent grant is positive for shareholders as it enhances the value of the company's intellectual property.
• The potential success of the Acclaim-3 trial could benefit patients with extensive stage small cell lung cancer.
• The company's employees may benefit from the company's progress and potential future success.

Next Steps

• Genprex will pursue additional patent applications in various countries.
• The company will continue to advance the Acclaim-3 clinical trial.
• Genprex will monitor the progress of its clinical trials and regulatory approvals.

Key Dates

Keywords

Reqorsa, Gene Therapy, Patents, PD-1 Antibodies, PD-L1 Antibodies, Lung Cancer, Acclaim-3, Clinical Trial, Intellectual Property, Singapore